Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T for Peritoneal Carcinomatosis
NCT03682744Phase 1Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR2 anti-CEA CAR-T cells in peritoneal carcinomatosis (PC), Peritoneal metastases and malignant ascites, sponsored by Sorrento Therapeutics. Primary endpoint: Number of Participants with Adverse Events at 16 weeks. Planned start Sep 2018; status: withdrawn.
02
Drugs
CAR2 anti-CEA CAR-T cells
03
Conditions
peritoneal carcinomatosis (PC)Peritoneal metastasesmalignant ascites
Beyond the preview
Go deeper on NCT03682744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682744.